IGF-1LR3

IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3)

IGF-1 LR3 is a synthetic 83-amino acid analog of human insulin-like growth factor. It is approximately 3x more potent than native IGF-1 with a 20–30 hour half-life due to reduced IGF-binding protein interaction.

Mechanism of Action

IGF-1 LR3 is a full IGF-1 receptor agonist with an N-terminal extension and R3 substitution that prevent sequestration by IGF-binding proteins, maintaining elevated free circulating levels.

This modification allows sustained receptor activation of the PI3K/Akt/mTOR and MAPK/ERK pathways, driving:

• Protein synthesis

• Satellite cell activation

• Muscle hypertrophy

• Muscle hyperplasia

The extended half-life (20–30 hours vs. 12–15 minutes for native IGF-1) enables once-daily dosing

Potential Benefits

• Approximately 2.5x greater anabolic response than native IGF-1 in animal models

• Muscle hypertrophy and hyperplasia through satellite cell activation

• Increased protein synthesis

• Accelerated wound healing

• Improved ligament and tendon recovery

• Enhanced nutrient partitioning

• Potential fat loss support

• Improved recovery and strength gains

• Sustained effects due to extended half-life
  

Why It's Being Researched

IGF-1 LR3 is being studied for its effects on muscle growth and tissue repair through a well-characterized growth factor pathway.

Animal studies demonstrated:

• Approximately 2.5x greater anabolic response than native IGF-1

• Increased satellite cell activation

• Enhanced tissue growth and repair

Interesting Facts

• Banned in competitive sports due to potent anabolic effects

• The R3 substitution and N-terminal extension prevent IGFBP binding, resulting in prolonged free IGF-1 activity

• Longer activity may increase efficacy but also increases toxicity risk

• Receptor desensitization may occur within 4–6 weeks

• Recovery periods may require equal or longer off-cycles

RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION